

Matrix Additions Part 2: Alternative Approaches for Rapid Pathogen Detection Methods

Organized by IAFP's Applied Laboratory Methods PDG

Moderator: Jaya Sundaram, WTI, Inc.

Sponsored By



Please consider making a contribution

This webinar is being recorded and will be available to IAFP members within one week.

Presenters

Amanda is the Technical Director of Food Safety at Midwest Laboratories, an ISO 17025 Accredited Laboratory in Omaha, NE. Here she oversees the operational and technical direction of the microbiology and food chemistry laboratories and ensures compliance of analytical and microbiological testing activities with applicable regulatory guidance. Amanda and the microbiology R&D team provide custom projects to clients including method verifications and validations, matrix extension studies, USP suitability/ preparatory testing, and product and process validations. She has her M.S. in Biology from the University of Nebraska at Omaha, with a research focus in molecular genetics and genome technology.



Nisha is a Senior Scientific Affairs Manager at Hygiena. She is responsible for overseeing third-party and internal product validations, certification maintenance/renewals, and global accreditations for multiple divisions within the company. Since joining Qualicon in 2001, Nisha has held a variety of positions within the R&D, Sales and Marketing, Applications and Validations groups. Nisha earned a Bachelor of Science degree in Medical Technology with a minor in Biology from the University of Delaware, and a Master of Science degree in Microbiology from Thomas Jefferson University in Philadelphia. She is also active on the AOAC Modification Task Force and the AOAC Advisory Council.



Introduction

- Food safety is everyone's responsibility
- FSMA has ignited rapid evolution in the food industry
- Professional Development Group (PDG) may provide recommendations, producer must decide whether the specific guidance is appropriate for their circumstances
 - Guidance based on various industry perspectives from four PDG publications
- Focus on US regulated products
 - Must adhere to all international, federal, state, and local laws and regulations related to your products and business



Resources

GENERAL INTEREST PAPER

Microbiological Detection Methods — Assuring the Right Fit

Patrick M. Bird,¹ Megan S. Brown,² Joy E. Dell’Ariaga,³ LeAnne A. Hahn,⁴ J. David Legan,⁵ Ryan D. Maus,⁶ Stephanie Pollard⁷ and Laurie S. Post⁸

¹W&B Biotech Consulting, 6260 Strathorn Dr., West Chester, OH 45390, USA
²Eurofins Microbiology Laboratories, Inc., 2100 Wright St., Madison, WI 53704, USA
³NordLabs, 1121 N. Main St., Lombard, IL 60148, USA
⁴Delbe Laboratories, Inc., 7100 N. Ridgeway Ave., Lincolnwood, IL 60712, USA
⁵Clear Labs, 3565 Heves Ave., Suite 2, Merrick Park, CA 94025, USA

SUMMARY

The food safety industry is in the midst of rapid evolution. Leaders and scientists alike are approaching new regulatory requirements set forth by the Food Safety Modernization Act to ensure analytical methods, designed to detect hazards, are fit for purpose for their specific commodities. Simultaneously, the food industry is innovating at a tremendous rate. Unique ingredients and formulations are being developed, novel processing methods are being deployed, and new products are entering the market. The food safety community is scrutinizing analytical approaches to ensure that new and existing methods are appropriate for the bery of products being tested. In addition, the industry is working to understand and agree upon the most prudent scientifically and economically sound approaches to method validation and verification. In this introductory article, the International Association for Food Protection Applied Laboratory Methods Professional Development Group discusses the needs and considerations for assessing fit-for-purpose approaches in the food analytical laboratory.

OVERVIEW

The first major change in U.S. food safety legislation since the Food Drug and Cosmetics Act of 1938 occurred in 2011, when the Food Safety Modernization Act (FSMA) was passed. This law emphasizes prevention of entry of foodborne contaminants into the market (3) and builds on approaches already implemented in industry, such as the Hazard Analysis Critical Control Point (HACCP) principles, to identify risks, apply control measures with defined critical limits, and verify effectiveness in mitigating those risks (3). FSMA calls these control measures “Preventive Controls” and requires that “the owner, operator, or agent in charge of a facility” must verify that their food safety preventive controls “are effective and significantly preventing the occurrence of identified hazards.” This demand for verification is driving a large

increase in laboratory testing, especially as food businesses expand environmental monitoring and increase the analysis of raw materials and finished products for pathogens, spoilage organisms, allergens and other adulterants. To facilitate this increase in testing, manufacturers are relying more and more on commercial or private laboratories to help them meet this demand by producing accurate results that are both efficient and cost effective.

In addition to testing that is driven by regulatory changes, globalization of the food supply, shorter product development timelines, and reformulation of existing products (4) to meet consumer trends create huge numbers of new food products that must be tested. In the U.S. alone, 21,435 new packaged food and beverage products for consumers were introduced in 2016, almost double the 11,853 introduced in 1998 (11). These new products may be the result of incremental changes, such as the advent of Greek yogurt, which grew from nothing in 2005 to 44% of the yogurt market by 2014 (10), or they may result from more radical innovations, such as the addition of probiotic cultures to various foods, including juices, chips, chocolate bars, pet food, and others. Products are also becoming more “exotic,” as in the case of insect-based foods (8) such as energy bars made from cricket flour. All such foods may come in multiple flavors, varieties (e.g., nonfat, sugar free), and forms (e.g., freeze-dried bites), resulting in a complexity of forms and formulations that may interfere with pathogen detection methods.

The USDA Trends in Food Recalls (12) reported a doubling in recalls between 2004 and 2013 and suggested a number of possible reasons, including:

- increased regulatory oversight
- increased product and environmental sampling
- improvements in technology and detection
- better product and ingredient traceability
- increased audits and inspections, and
- new food types available in the market.

*Author for correspondence: Phone: +1 608.940.3137; +1 540.953.8989; Email: meganbrown@eurofins.com, stephanie.pollard@clearlabs.com

GENERAL INTEREST PAPER

Alternative Approaches for Qualitative Microbiological Method Matrix Additions

Megan S. Brown,¹ Patrick M. Bird,² Sharon Brunella,³ W. Evan Chaney,⁴ Charles A. Kennett,⁵ J. David Legan,⁶ Ryan D. Maus,⁷ Laurie Post⁸ and Stephanie Pollard⁹

¹Eurofins Microbiology Laboratories, Inc., 2100 Wright Street, Madison, Wisconsin 53704, USA
²W&B Biotech Consulting, 6260 Strathorn Drive, West Chester, Ohio 45390, USA
³Biorisk Biotech Consulting, 6602 N.W. Burgundy Drive, Corvallis, Oregon 97330, USA
⁴Diamond V, 2525 83rd Avenue S.W., Cedar Rapids, Iowa 52404, USA
⁵TruHaven Foods, 2015 Spring Road, Oak Brook, Illinois 60523, USA
⁶Delbe Laboratories, Inc., 7100 N. Ridgeway Avenue, Lincolnwood, Illinois 60712, USA
⁷Clear Labs, 3565 Industrial Road, San Carlos, California 94070, USA

SUMMARY

Most commonly used pathogen detection methods have undergone a rigorous validation through third-party certification bodies such as AOAC INTERNATIONAL, Association Française de Normalisation, MicroVal, and others. These validations focus on sensitivity, robustness, and inclusivity and exclusivity of the assay target(s) for the matrices submitted to the certification body. This creates a list of officially validated matrices that falls far short of what is seen routinely during end-user testing. Thorough validation of all matrices at all test portion sizes is neither cost efficient, practical, nor arguably necessary. Here, we provide guidance on alternate evaluation approaches using a food-similarity grouping and a risk-based questionnaire to help end-users determine an appropriate level of evaluation of their method of choice. In reducing the burden of evaluation for many matrices, these alternative approaches may allow more methods to be evaluated, thus strengthening confidence in method application and ultimately leading to a safer food supply.

OVERVIEW

The Food Safety Modernization Act, passed in 2011, emphasizes prevention of entry of foodborne contaminants into the market (33). This act focuses on the establishment of verified “preventive controls” to reduce or eliminate identified hazards in the food production environment. This has led not only to a dramatic increase in laboratory testing of raw ingredients, finished food products, and environmental samples but also to questions on what “verified” means. Most foodborne pathogen test methods are validated for specific applications by a third-party certification body such as AOAC INTERNATIONAL (AOAC), Association Française de Normalisation, MicroVal, NordVal International, or Health Canada. However, third-party validation studies often include only a small number of matrices or a different test portion size than is commonly tested in the field (e.g., 25 versus 375 g, respectively). Because test methods cannot

validated for every possible matrix at every test portion size, there is a substantial gap in data between third-party certified methods and end-user fit-for-purpose analytical testing needs. In this article, we aim to provide suggestions for practical, risk-based approaches to address that gap in qualitative microbiological methods by focusing on matrix grouping and levels of test method evaluation. In support of this aim, we have created a Matrix Evaluation Level Assessment Tool (available at <https://www.foodprotection.org/wp/downloads/library/matrix-evaluation-level-assessment-tool.xlsx>) that guides the user through a set of questions to help determine the degree of test method evaluation needed for a new matrix.

Need for alternative method evaluation approaches

Rapid methods for the qualitative microbiological testing of foods are used extensively throughout the food industry for detection of low concentrations of pathogens. Typically, method validation studies are conducted through recognized third-party certification bodies by the rapid method developer or test kit manufacturer with a limited group of food matrices and associated method parameters such as test portion size, nutrient media, and enrichment conditions. Because the scope of the validation is limited to the matrices included in the method validation study, the responsibility for ensuring that the methods are fit-for-purpose is left to end-users such as food manufacturers and third-party laboratories. This responsibility often means conducting matrix addition studies to extend the method scope to a new matrix or a new test portion size. Here, we use the term “evaluation” to encompass the process by which test methods are assessed for use with a matrix of interest. This is an attempt to distinguish this work from definitions of verification or validation used by regulatory and accreditation bodies.

*Author for correspondence: Phone: +1 608.940.3137; Email: meganbrown@eurofins.com

GENERAL INTEREST PAPER

Evaluating Microbiological Method Equivalence – A Decision Guide

J. David Legan,¹ Laurie Post,² Christina Barnes,³ Amanda Brookhouse-Sisney,⁴ W. Evan Chaney,⁵ Nisha Corrigan,⁶ Kristen A. Hunt,⁷ Ryan D. Maus,⁸ Sophie Pierre,⁹ Patricia Rule,¹⁰ Nikki Taylor,¹¹ and Julie Weller¹²

¹Eurofins Microbiology, 6034 Ronald Reagan Ave., Madison, WI 53704, USA
²Delbe Laboratories Inc., 7100 N. Ridgeway Ave., Lincolnwood, IL 60712, USA
³2410 Conway Ave., 3M Building 9500-801, St. Paul, MN 55144-1000, USA
⁴Midwest Laboratories, 13611 E. St., Omaha, NE 68144, USA
⁵Diamond V, 2525 83rd Ave. SW, Cedar Rapids, IA 52404, USA
⁶Hygiena, 941 Avenida Acaso, Camarillo, CA 93012, USA
⁷Bo-Rad, 3 Boulevard Raymond Poincaré, 98430 Marnes-la-Coquette, France
⁸bioMérieux, Inc., 505 Anglin Road, Hazelwood, MO 63042, USA

SUMMARY

Using an appropriate method is a key step in generating reliable results; and, when those results are to be used to make safety-critical decisions, method selection becomes even more important. For microbiological testing, there are national and international standard methods and various other widely accepted methods. Performance of such methods has usually been validated through some kind of collaborative process or independent review. An independent review may have resulted in some kind of certification. Method validation, with or without independent certification, demonstrates that a method has performance equivalent to an established reference method. Many circumstances can arise that cause a laboratory to change methods. In such an event, how is a laboratory to determine that two methods are equivalent to one another if neither of them is a reference method? In this paper we outline a thought process to guide this decision. The process involves comparing existing validation and/or certification data to determine whether two or more methods have been compared against the same reference method for the matrix of interest using a rigorous experimental and statistical approach. If they have, the methods may be considered equivalent, and a laboratory simply needs to verify its ability to perform them. If they have not, then a formal validation may be needed.

OVERVIEW

In previous articles by the International Association for Food Protection Interest Group on Verification and Validation, the increasing need for the most prudent, scientifically and economically sound approaches to method validation and verification was discussed (3). Suggestions for practical, risk-based approaches to address this need focused on matrix

*Author for correspondence: Phone: +1 608.940.3137; Email: David.Legan@eurofins.com

GENERAL INTEREST PAPER

Selection of Pathogen Strains for Evaluating Rapid Pathogen Test Methods Applied to New Matrices

J. David Legan,¹ Christina Barnes,² Amanda Brookhouse-Sisney,³ Megan S. Brown,⁴ W. Evan Chaney,⁵ Nisha Corrigan,⁶ Wilfredo Dominguez,⁷ Gabriela Lopez Velasco,⁸ Ryan D. Maus,⁹ Laurie Post,¹⁰ and Julie Weller¹¹

¹Eurofins Microbiology, 6034 Ronald Reagan Ave., Madison, WI 53704, USA
²Hygiena, 941 Avenida Acaso, Camarillo, CA 93012, USA
³Diamond V, 2525 83rd Ave. SW, Cedar Rapids, IA 52404, USA
⁴Delbe Laboratories Inc., 7100 N. Ridgeway Ave., Lincolnwood, IL 60712, USA
⁵3M Center, St. Paul, MN 55144-1000, USA
⁶Midwest Laboratories, 13611 E. St., Omaha, NE 68144, USA
⁷Urbana Inc., 504 Genomic Dr., Madison, WI 53719, USA


SUMMARY


Before first use of a validated method, laboratories verify their ability to apply the method as designed. In routine laboratory operations, new matrices will appear occasionally, with insufficient data ensuring method performance for the matrix. Approaches have been documented to the “fitness for purpose” testing then required, but the question of how to select the pathogen strain or strains for this activity has received scant attention. This article reviews approaches that may influence strain selection for method evaluation, including processing environment, geographical origin or proximity, seasonality, environmental factors, intrinsic characteristics of matrices, public health data, and the logistics, cost, and complexities involved in managing large challenge-strain collections. We conclude that food safety is served best when laboratories conduct method application studies for new matrices with one or more appropriately stressed members of a small, conveniently managed panel of challenge strains. However, if stakeholders have clear knowledge of a strong link between the matrix and a particular strain of concern, that would be a reason to favor acquisition and use of that strain. The worst approach is to not conduct application studies because of perceived limitations in accessing one or more highly specific strains.


OVERVIEW


Analytical methods for detecting microbial pathogens must be validated. Method validation is defined in International Standards Organization (ISO) 14140-2 (4) as “the establishment of the performance characteristics of a method and provision of objective evidence that the performance requirements for a specific intended use are fulfilled.” Validation is a rigorous experimental process that examines inclusivity, exclusivity, sensitivity, and robustness.

*Author for correspondence: Phone: +1 608.940.3076; Email: David.Legan@eurofins.com

 [Microbiological Detection Methods – Assuring the Right Fit](#)

 [Alternative Approaches for Qualitative Microbiological Methods Matrix Additions](#)

 [Evaluating Microbiological Method Equivalence – A Decision Guide](#)

 [Selection of Pathogen Strains for Evaluating Rapid Pathogen Test Methods Applied to New Matrices](#)

Matrix Additions Part 1: Recap

- Verification vs. Validation
- Understand the gap(s) in the scope of validation for rapid pathogen detection methods
- Risk assessment for method performance
- Food matrix grouping based on intrinsic properties
- Selecting enrichment conditions for a matrix evaluation study

Rapid Pathogen Detection Methods

- Certified and/or validated qualitative methods readily available from test kit providers for significant pathogens
- “Fully validated”= AOAC Official Method of Analysis (OMA)
 - Interlaboratory study
- Assay is developed by kit manufacturer
 - Nucleic acid-based: PCR, multiplex PCR, real-time PCR, nucleic acid sequence-based amplification (NASBA), loop-mediated isothermal amplification (LAMP) and DNA microarray
 - Immunoassays: ELISA and lateral flow



AOAC OMA vs. AOAC PTM

TABLE 1. Comparison between AOAC and ISO 16140-2 certification requirements for qualitative methods

| Study | AOAC appendix J (1) | | ISO 16140-2:2016 (9) |
|----------------------------------|---------------------|----------------|----------------------|
| | PTM submission | OMA submission | |
| Inclusivity/exclusivity | X | X | X |
| Matrix suitability: ^a | | | |
| POD/dPOD | X | X | |
| LOD ₅₀ /RLOD | | | X |
| Multicomparison | | | X |
| Robustness | X | | |
| Lot to lot consistency | X | X | |
| Interlaboratory/collaborative | | X | X |

^aPOD, probability of detection, defined as number of positive samples divided by total number of samples in a fractional recovery study; dPOD, difference between probabilities of detection of candidate and reference methods; LOD₅₀, limit of detection, the level of contamination with an expectation of 50% positive test results; RLOD, relative level of detection, the ratio of the LOD of the alternative method and the LOD of the reference method.

TABLE 2. Comparison between AOAC and ISO 16140-2 certification requirements for quantitative methods

| Study | AOAC appendix J (1) | | ISO 16140-2:2016 (9) |
|---------------------------------|---------------------------|------------------------------|----------------------|
| | Performance tested method | Official methods of analysis | |
| Inclusivity/exclusivity studies | X | X | X |
| Matrix suitability | X | X | |
| Accuracy profile | | | X |
| Relative trueness profile | | | X |
| Limit of quantification | | | (X) |
| Robustness | X | | |
| Lot to lot consistency | X | X | |
| Interlaboratory/collaborative | | X | X |

AOAC Matrix Claim

- Scope of matrices included in the validation study & stated in the intended use (applicability statement of the method)
- Broad range of foods claim: 15 matrices from 5 categories
 - ISO 16140-2:2016, Annex A
Classification of sample types
- Even with a broad range claim, **the specific foods tested need to be evaluated**

Table 1: Acceptable Multiple Matrix Claims

| Multiple Matrix Claim | Criteria | |
|------------------------|-----------------------|------------------------------------------|
| | Number of Matrices | Number of Categories/Groups ¹ |
| Broad Range of Foods | 15 (3 foods/category) | 5 categories |
| Variety of Foods | ≥ 10 | 5 categories |
| Selected Foods | ≥ 5 | 2 categories |
| Food Category/Group | ≥ 5 | 1 category |
| Environmental Surfaces | 7 | Not applicable |
| Selected Surfaces | 2-6 | Not applicable |

| | |
|-----------------------------------------------------------|---------------------------------------------------|
| Raw milk and dairy products | Fresh produce and fruits |
| Heat-processed milk and dairy products | Processed fruits and vegetables |
| Raw meat and ready-to-cook meat products (except poultry) | Dried cereals, fruits, nuts, seeds and vegetables |
| Read-to-eat, ready-to-reheat meat products | Infant formula and infant cereals |
| Raw poultry and ready-to-cook poultry products | Chocolate, bakery products and confectionary |
| Read-to-eat, ready-to-reheat meat and poultry products | Multicomponent foods or meal components |
| Eggs and egg products (derivatives) | Pet food and animal feed |
| Raw and ready-to-cook fish and seafoods (unprocessed) | Environmental samples (food or feed production) |
| Ready-to-eat, ready-to-reheat fishery products | Primary production samples (PPS) |

Why are matrix evaluations needed?

Scope is limited to the matrices included in the method validation study

Example: 10 matrices included in the validation study



Kit producer may have an additional library of validated matrices

Example: 85 validated by kit supplier



Tens of thousands of food products on the market

Thorough validation of ALL matrices at all test portion sizes is not cost-efficient or feasible

Alternative evaluation approaches are necessary



Matrix Evaluation/ Extension Study

- Process by which test methods are assessed for use with a **matrix of interest**
- Ensure the method is fit-for-purpose for the end user
 - Food manufacturers and/or third-party labs
- To extend the use of a method to a new food or foods not included in the original method validation
- Larger test portion size



Method Overview

1. Enrichment

- Sample size (test portion)
- Enrichment media
 - Dilution ratio
 - Enrichment time and temp



1 ENRICH
Collect your sample and mix it with enrichment media.



2 INCUBATE
Allow the sample to incubate for a designated time. Perform secondary enrichment if necessary.



3 LYSE
Add sample to BAX[®] Lysis Reagent and heat to rupture cell wall and release DNA into solution.

2. Sample preparation (Hands-on time)

3. Detection method (Instrument)


- Result interpretation



4 HYDRATE
Transfer lysate to the pellet in each PCR tube.



5 LOAD
Place PCR tubes into the BAX[®] System instrument. You can then work on other tasks while the BAX[®] System amplifies and detects.



6 REVIEW
Results are displayed as clear yes or no icons in about one hour for most assays.

***Each part of the method is important for accurate detection of the target analyte**

Considerations

- Has the method been validated for that product matrix?
 - If not, is the food category/type that has been validated close enough to your sample type?
 - Have the test portion size, enrichment dilution and incubation time and temp been validated?



Test Portion

The part of the “sample” that is actually tested by the laboratory

Composite test portions

- Lower limit of detection of the method (i.e., 1 CFU per 25 g versus 1 CFU per 375 g)
- **Rigorous evaluation is highly recommended**

"Test 375 g"

- Greater the test portion will increase the sensitivity

... but the method has only been validated at 25 g




Fig. 1. Pooling and initial suspension preparation for reference (25 g) and pooled (375 g) sample size.

*don't forget that you need a statistically valid sampling plan!

Sample Enrichment

- Foundation for detection of pathogens



Follow protocol as validated


Media, time, temperature, dilution ratio

Example: **Reduction in enrichment dilution ratio requires validation**

375g refrigerated ground beef in
1.5L of enrichment media

✘ Delays in enrichment time/temp = Issues with recovery

➡ 45°C for pre-warm temperature



375g Test Portions

- May not be applicable to all matrices
- Example: spices at 25 g using molecular method
 - Enriched in 220 mL skim milk + 230 mL BPW (450 mL media)
 - 375 g sample = scale up 15 times
 - 6.75 Liters of Media = almost 2 gallons
 - Not cost effective or feasible



Sample Size and Dilution Ratio

AOAC TB 2023-001

1. If there is **any change in the dilution ratio**, that change shall be validated
2. If a method has an approved validation with a certain test portion size, then the validated claim for that method may include portions up to that test portion size
 - **To claim a test portion size above higher than the approved validated test portion size**, then validation is required



AOAC Official MethodsSM Program

TECHNICAL BULLETIN

AOAC TB 2021-001 – Sample Size and Dilution Ratio (Microbiology)

OMB Approval Date: 10-2021

Effective Date: 11-2021

Subject/Title: Sample Size and Dilution Ratio (Microbiology)

Intended Use: Validation Guidance for Methods – Microbiology for Food and Environmental Surfaces

1. If there is any change in the dilution ratio, that change shall be validated¹.
2. If a method has an approved validation with a certain test portion size, then the validated claim for that method may include portions up to that test portion size. To claim a test portion size above higher than the approved validated test portion size, then validation is required².

¹ **Note:** Methods cannot claim a different test portion to the enrichment broth ratio of a given matrix than that of the ratio of the approved validation. Any such change must be validated. A smaller test portion size of the same matrix may be claimed if the portion to broth ratio is the same as the larger portion to broth that was validated.

² **Note:** AOAC reserves the right to require validation data to support any deviation in test portion size that is not equal to the test portion size in the approved validation. The smallest acceptable test portion size claimed must be greater than or equal to the smallest portion for the reference method used as part of the approved validation.

Potential Inhibitors

- Antimicrobial constituents
 - Example: herbs and spices have antimicrobial or bacteriostatic properties
- Growth inhibitors
 - Example: enzymes and polyphenols
- Molecular inhibitors
 - PCR: collagen, humic acid, calcium ions, and polyphenolic compounds
- Dilution, neutralization or alternative treatment to remove inhibition



Table B.1 — Example of (food) items and its characteristics

| Category | Item | Challenging characteristic |
|----------|------|-----------------------------------|
| 1 | 1 | pH |
| 2 | 2 | Viscosity |
| 3 | 3 | Fat content |
| 4 | 4 | High background microbiota and pH |
| 5 | 5 | Polyphenol |


Method Modifications

- For example:
 1. New matrix addition, new media enrichment/time/temperature
 2. New instrumentation
 3. Modification to reagents, manufacturing locations/process
- May or may not affect the established validated performance parameters of the original method
- No “one size fits all” rule or set of rules to govern how modifications will be addressed
 - 🧪 Some may only necessitate verification
 - 🧪 Other modifications may require significant validation data to support their use



Fit For Purpose

For Use with Products Regulated in the U.S. (e.g. FDA or USDA-FSIS)



**Disclaimer: dependent on your geographical location and regulatory body*

Not included: ISO 16140-3

- Different regulatory requirements for different agencies depending on your geographical location

Microbiology of the food chain — Method validation —

Part 3: Protocol for the verification of reference methods and validated alternative methods in a single laboratory

Microbiologie de la chaîne alimentaire — Validation des méthodes —

Partie 3: Protocole pour la vérification dans un seul laboratoire de méthodes de référence et de méthodes alternatives validées

Publication ISO 16140-3 'Method verification' – improving confidence in laboratory

 **Tuesday 2 March 2021**
online two sessions



<https://vimeo.com/522329760>

Table 3 — Protocols to determine eLOD₅₀ and number of replicates needed per inoculation level

| Protocol | Inoculation level of the test portion | | | | | Total number of replicates |
|----------|-------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------|---------------------------------|-------|----------------------------|
| | High level 9 × LOD ₅₀ / test portion | Intermediate level 3 × LOD ₅₀ / test portion | Low level 1 × LOD ₅₀ / test portion | 3 cfu to 5 cfu /test portion | Blank | |
| 1 | 1 | 4 | 4 | – | 1 | 10 |
| 2 | – | 3 | 5 | – | 1 | 9 |
| 3 | – | – | – | 7 | 1 | 8 |

NOTE The abbreviation of colony forming units is cfu.

Matrix Evaluation/ Extension Study

TABLE 4. Evaluation levels

| Evaluation level | Number of spiked test portions | Inoculation level, CFU/test portion | Inoculating cells | Analysis |
|----------------------------|--------------------------------|-------------------------------------|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Full matrix validation | 5 | 2-10 | Fresh culture or heat stressed | Presumptive results compared with confirmation results and reference method to demonstrate no statistical difference between the methods |
| | 20 | 0.2-2 | | |
| | 5 | 0 | | |
| Moderate matrix evaluation | 2 | 2-10 | Fresh culture or heat stressed | Presumptive results compared with confirmation results to demonstrate no deviation in candidate method result compared to culture confirmation |
| | 10 | 0.2-2 | | |
| | 2 | 0 | | |
| Minimal matrix evaluation | 1-7 | 20-30 | Fresh culture or heat stressed | Candidate detection results for inoculated and uninoculated samples should match input |
| | 0-1 | 0 | | |

*abbreviated studies may save time and money; they do come with added limitations as a result of the reduced scope of the data obtained

Strain Selection

- Sourced from the same or similar matrix or is commonly isolated from matrix, when possible
 - Strain of interest might now be included in the list of method developers list of strains from the validation
 - For example: outbreak strain not included in inclusivity data- test to see if method detects
- Small in-house and commercial labs may not have the resources
 - Gather, identify and isolate strains or serotypes from naturally contaminated samples
 - Ability to maintain large collections

= Utilize commercially available standardized strains
- Rely on the inclusivity data produced during a method's validation and/or accreditation (see AOAC certificate)

TABLE 2. *Salmonella* serotypes associated with chocolate outbreaks

| <i>Salmonella</i> serotype | Alternate strain source | Alternate strain origin | Vehicle | Outbreak date | Reference |
|----------------------------|-------------------------|------------------------------------------------------------|--------------------|---------------|-----------|
| Durham | NA ^a | NA | Cocoa powder | 1972 | (30) |
| Eastbourne | NCTC 5771 | Kauffmann F State Serum Institute, Copenhagen | Chocolate products | 1974 | (16, 72) |
| Napoli | NCTC 6853 | Italian food handler | Chocolate bars | 1982 | (31, 34) |
| Nima | NA | NA | Chocolate coins | 1985–1986 | (38) |
| Typhimurium | ATCC 14028 | Heart and liver from 4-week-old chickens | Chocolate products | 1987 | (48) |
| Oranienburg | ATCC 9239 | Outbreak of food poisoning at an Illinois state hospital | Chocolates | 2001–2002 | (90) |
| Montevideo | ATCC BAA-710 | Human clinical specimen: salmonellosis from tomatoes, 1993 | Chocolate tablets | 2006 | (23) |

^aNA. not applicable.

TABLE 3. Common *Salmonella* serovars available from ATCC on 2 February 2021, with geographical and other source indications

| Serovar | Isolates in the ATCC catalog | Geographical association | | | | | | Other association | | |
|-------------|------------------------------|--------------------------|---------------|----------------|--------------|------------|------------|-------------------|----------|--------|
| | | SE US (86) | Maryland (66) | Louisiana (53) | Seattle (62) | India (50) | Egypt (22) | General | Clinical | Common |
| Typhimurium | 61 | X | X | | X | X | X | X | X | X |
| Enteritidis | 10 | X | X | X | X | X | X | X | X | X |
| Thompson | 4 | | | X | | | | | | X |
| Montevideo | 2 | | | X | | X | | | X | |
| Newport | 2 | | | | | X | | | X | |
| Pullorum | 2 | | | | | X | | X | | |
| Senftenberg | 2 | | | | X | | | X | X | X |
| Braenderup | 2 | | | X | | | | | | |
| Cerro | 2 | | | | | | | | X | X |
| Anatum | 2 | | | | | | | | | X |
| Javiana | 2 | | | | | | | | | X |
| Virchow | 1 | | | | | | | X | | |
| Dublin | 1 | | | | | | | | X | X |
| Worthington | 1 | | | | | | | | | X |
| London | 1 | | | | | | | | | X |
| Muenchen | 1 | | | | | | | | | X |
| Bredeney | 1 | | | | | | | | | X |
| Hadar | 1 | | | | | | | | | X |
| Mississippi | 1 | | | | | | | | | X |

Spiking Procedures for Minimal/ Moderate Matrix Evaluations

Liquid inoculum often used

- Serial dilutions of overnight growth to achieve the targeted inoculation level
- Purchase quantified reference cultures

Best practice is to use appropriately stressed cultures when possible

- Example 1: dry powders + lyophilized cultures
- Example 2: ready-to-eat deli meat + heat stressed culture
- Example 3: frozen vegetables + heat stressed, then frozen culture
- Example 4: perishable items + unstressed culture



Using the Risk-Assessment Tool

- Follow along: link sent in webinar materials
- Tool is accessible through the International Association for Food Protection Applied Laboratory Methods Professional Development Group homepage:
<https://www.foodprotection.org/upl/downloads/library/matrix-evaluation-level-assessment-tool.xlsx>

Example #1: *Salmonella* in Hard-Boiled Eggs

- AOAC-OMA Immunoassay validated for a **broad range of foods**
- Food category: Eggs and egg products (derivatives) ✓

| | | | |
|---------------|----------------------------------------------|-----|---------------|
| Liquid eggs | <i>Salmonella enterica ser. Enteritidis</i> | 25g | FDA-BAM Ch. 5 |
| Powdered eggs | <i>Salmonella enterica ser. Choleraesuis</i> | 25g | FDA-BAM Ch. 5 |



VS.



Matrix extension



Validated matrices

Method Parameters:

1. Test portion= 25g
2. Enrichment media= BPW
3. Dilution ratio= 1:10
4. Time= 18-24 hours
5. Temp= 35°C

Matrix Evaluation Level Assessment Tool

[Home](#)

For Use with Products Regulated in the U.S. (e.g. FDA or USDA-FSIS)

Estimate of need for validation or verification

| No. | Question | Action on response | |
|-----|-------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------|
| | | Yes | No |
| 0 | Is the method validated for this specific matrix, test portion size and enrichment ratio? | Fit for purpose. Free to use without further evaluation | Go to 1 |
| 1 | Is the method validated at all? | Go to 2 | Conduct a single laboratory method validation study |
| 2 | Is the method validated for a broad range of foods*? | Go to 3 | Go to 5 |
| 3 | Has a similar matrix with the same test portion size and enrichment ratio been validated? | Go to 4 | Go to 5 |
| 4 | Perform Fit-for-Purpose Test. | See "Fit-for-Purpose Test Options" Tab | |
| 5 | Conduct risk assessment to determine level of evaluation required. | See "Risk Assessment" Tab | |

*Broad range of foods is defined as at least 15 unique matrices across three food categories. Food categories can be found in ISO 16140-2 Annex A.

Fit-For-Purpose Study

[Home](#)

Recommended Fit-for-Purpose Study Design:

| Option | Method | Inoculation level (CFU / test portion) | Number of test portions | Analysis |
|-----------------------|------------------|----------------------------------------|-------------------------|---------------------------------------------------------|
| Fit-for-Purpose Assay | Candidate method | 20-30 | 3 | See Fit-for-Purpose Result Analysis Tab |
| | | 0 | 3 | |
| | Reference method | 20-30 | 3 | |

Additional Fit-for-Purpose Study Designs

| Option | Inoculation level (CFU / test portion) | Method | Number of test portions | Expected Result | Notes |
|----------------------------------------------------|----------------------------------------|------------------|-------------------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FDA 5.1.1 Matrix Verification FDA Emergency Use | 20-30 | Candidate method | 7 | 7/7 positive | Once 7/7 OR 19/20 spikes are recovered consider matrix verified: no further evaluation necessary. May be performed in parallel with test samples, results of which will be invalidated if spikes are not recovered. |
| | | | 20 | 19/20 positive | |
| USP style Suitability Test | 20-30 | Candidate method | 1 | 1/1 positive | |

Fit-For-Purpose Study Results

| Outcome | Method | Detection Results (Correct result / Number tested) | | Explanation and response |
|---------|------------------|----------------------------------------------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | Inoculated (expected positives) | Non-inoculated controls (expected negatives) | |
| 1 | Candidate method | 3/3 | 3/3 | Candidate method is suitable for use with this matrix. Further evaluation is not needed but may be conducted if desired. |
| | Reference method | 3/3 | N/A | |
| 2 | Candidate method | 2/3 | 3/3 | Lack of detection in one of the inoculated samples suggests matrix interference with the assay or pathogen growth issues. Consider dilution, neutralization or alternative treatment to remove inhibition, then repeat Fit-for-Purpose test. If still fails, consider alternative method / platform |
| | Reference method | 3/3 | N/A | |
| 3 | Candidate method | 3/3 | 3/3 | Suggests matrix inhibition during enrichment with reference method and/or a candidate method that is more sensitive than the reference method. Another possibility is that the inoculum level is much lower than intended. However, candidate method passes Fit-for-Purpose Test and can be used. |
| | Reference method | <3/3 | N/A | |
| 4 | Candidate method | <3/3 | 3/3 | Suggests matrix interference with enrichment. Consider dilution or preenrichment medium additive (e.g. Tween) to mitigate matrix interference, then repeat Fit-for-Purpose Assay. If still fails, consider alternative method / platform. |
| | Reference method | <3/3 | N/A | |
| 5 | Candidate method | <3/3 | <3/3 | A "false positive" combined with a "false negative" suggests the samples could have been switched. Investigate. If confirmed, address laboratory procedures and rerun the Fit-for-Purpose Assay. |
| | Reference method | 3/3 | N/A | |
| 6 | Candidate method | 3/3 | <3/3 | Suggests matrix was contaminated before use, or was cross-contaminated in the laboratory. Investigate including use of confirmatory testing: - If cross-contaminated in the laboratory, address laboratory procedures and rerun Fit-for-Purpose Assay, - If investigation excludes laboratory contamination, suggesting the matrix was contaminated as tested, consider your reporting responsibilities. |
| | Reference method | 3/3 | N/A | |

Example #2: *L. monocytogenes* in Vanilla Pudding

- AOAC-OMA LAMP assay validated for queso fresco, **vanilla ice cream**, 4% milk fat cottage cheese, 3% chocolate whole milk
- Food category: Heat-processed milk and dairy products ✓



Validated matrix

VS.



Matrix extension

Method Parameters:

1. Test portion= 25g
2. Enrichment media= UVM Broth
3. Dilution ratio= 1:10
4. Time= 24-28 hours
5. Temp.= 35°C

Matrix Evaluation Level Assessment Tool

[Home](#)

For Use with Products Regulated in the U.S. (e.g. FDA or USDA-FSIS)

Estimate of need for validation or verification

| No. | Question | Action on response | |
|-----|-------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------|
| | | Yes | No |
| 0 | Is the method validated for this specific matrix, test portion size and enrichment ratio? | Fit for purpose. Free to use without further evaluation | Go to 1 |
| 1 | Is the method validated at all? | Go to 2 | Conduct a single laboratory method validation study |
| 2 | Is the method validated for a broad range of foods*? | Go to 3 | Go to 5 |
| 3 | Has a similar matrix with the same test portion size and enrichment ratio been validated? | Go to 4 | Go to 5 |
| 4 | Perform Fit-for-Purpose Test. | See "Fit-for-Purpose Test Options" Tab | |
| 5 | Conduct risk assessment to determine level of evaluation required. | See "Risk Assessment" Tab | |

*Broad range of foods is defined as at least 15 unique matrices across three food categories. Food categories can be found in ISO 16140-2 Annex A.

Example #2: *L. monocytogenes* in Vanilla Pudding

| Risk assessment for suggested evaluation level | | | | | | |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------------------------|--------------------|----------------------------------------------|------------|
| No. | Question | Yes | | No | | Your score |
| | | Score | If Yes, Next Step: | Score | If No, Next Step: | |
| 5A | Does the matrix fit into an AOAC or ISO 16140-2:2016 group (and subcategory - if listed) containing a validated representative example? | 0 | Go to 5B | 10 | Go to 7A | 0 |
| 5B | Is the similar representative example (from 5A) validated at the intended test portion size, or larger? | 0 | Go to 5C | 0 | Go to 5D | 0 |
| 5C | Is the similar representative example (from 5A) validated at the intended enrichment ratio? | 0 | Go to 6A | 0 | Go to 5D | 0 |
| 5D | Does the matrix have a high risk association with the target analyte? | 10 | Go to 6A | 4 | Go to 6A | 4 |
| 6A | Does the new matrix contain inclusions (e.g. ice cream with almonds vs ice cream)? | 0 | Go to 6B | 0 | Go to 7A | |
| 6B | Is the matrix inclusion representative of a matrix already validated by the method? | 0 | Go to 6C | 5 | Go to 7A | |
| 6C | Is the new matrix inclusion enrichment procedure the same as the validated representative example (e.g. do almonds have the same enrichment procedure as ice cream)? | 0 | Go to 7A | 2 | Go to 7A | |
| 7A | Does the matrix or any inclusions present have known ability to inhibit growth of the organism in enrichment or method detection chemistry? | 0 | Go to 7B | 0 | Assessment is complete | 0 |
| 7B | Has a Fit-for-Purpose Test been performed? | 0 | Go to 7C | 5 | Assessment is complete | |
| 7C | Were the results of the Fit-for-Purpose Test acceptable? (e.g. recovery of all inoculated samples) | 0 | Assessment is complete | Ignore Score Total | Refer to Fit-for-Purpose Result Analysis Tab | |
| Total: | | | | | | 4 |

Example #2: *L. monocytogenes* in Vanilla Pudding

Risk Assessment Score:

[Return to risk assessment](#)

Test Method Evaluation Levels


Test method evaluation levels and associated study design schemes determined by risk assessment scoring system.

| Level | Inoculation level | Inoculation level, CFU | Number of test portions | Inoculating Cells | Analysis | When to Use: | Notes |
|----------------------------|-------------------|------------------------|-------------------------|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Full Matrix Validation | High | 20-30 | 5 | Fresh culture or stressed e.g. by heat, drying or freezing | Presumptive results compared to reference method. Equivalent results required as determined by dPOD calculations. | Risk assessment score of 13+ | If no published validation exists, validation must demonstrate the inclusivity and exclusivity of the method. If a narrow published validation includes inclusivity and exclusivity studies, these need not be repeated. "Low " inoculation level should give 25 - 75 % positivity rate. |
| | Low | 0.2-5 | 20 | | | | |
| | None | 0 | 5 | | | | |
| Moderate Matrix Evaluation | High | 20-30 | 2 | Fresh culture or stressed e.g. by heat, drying or freezing | Presumptive results compared to reference method. | Risk assessment score of 6-12 | |
| | Low | 0.2-5 | 10 | | | | |
| | None | 0 | 2 | | | | |
| Minimal Matrix Evaluation | High | 20-30 | 1 - 7 | Fresh culture or stressed e.g. by heat, drying or freezing | 100 % correct response | Risk assessment score of 2-5 | |
| | None | 0 | 0-1 | | | | |

All matrices should be processed at intended-use test portion size and enrichment protocol

“Minimal Matrix Evaluation”

- Recommended for a risk assessment score of **2 to 5**
- Screen for obvious detection issues
1-7 spiked test portions and
0-1 uninoculated samples
- Test portion spiked with < 30 CFU
of the target analyte
 - 7/7 spikes show recovery of the organism
- **Matrix spikes yield positive results = verified**
- Uninoculated sample(s) do not have cross-reaction (false positive)



Example #3: *L. monocytogenes* in Strawberry Ice Cream



Validated matrix

VS.



Matrix extension

Inclusion= strawberry pieces

| Risk assessment for suggested evaluation level | | | | | | |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------------------------|--------------------|----------------------------------------------|------------|
| No. | Question | Yes | | No | | Your score |
| | | Score | If Yes, Next Step: | Score | If No, Next Step: | |
| 5A | Does the matrix fit into an AOAC or ISO 16140-2:2016 group (and subcategory - if listed) containing a validated representative example? | 0 | Go to 5B | 10 | Go to 7A | 0 |
| 5B | Is the similar representative example (from 5A) validated at the intended test portion size, or larger? | 0 | Go to 5C | 0 | Go to 5D | 0 |
| 5C | Is the similar representative example (from 5A) validated at the intended enrichment ratio? | 0 | Go to 6A | 0 | Go to 5D | 0 |
| 5D | Does the matrix have a high risk association with the target analyte? | 10 | Go to 6A | 4 | Go to 6A | |
| 6A | Does the new matrix contain inclusions (e.g. ice cream with almonds vs ice cream)? | 0 | Go to 6B | 0 | Go to 7A | 0 |
| 6B | Is the matrix inclusion representative of a matrix already validated by the method? | 0 | Go to 6C | 5 | Go to 7A | 5 |
| 6C | Is the new matrix inclusion enrichment procedure the same as the validated representative example (e.g. do almonds have the same enrichment procedure as ice cream?) | 0 | Go to 7A | 2 | Go to 7A | |
| 7A | Does the matrix or any inclusions present have known ability to inhibit growth of the organism in enrichment or method detection chemistry? | 0 | Go to 7B | 0 | Assessment is complete | 0 |
| 7B | Has a Fit-for-Purpose Test been performed? | 0 | Go to 7C | 5 | Assessment is complete | 5 |
| 7C | Were the results of the Fit-for-Purpose Test acceptable? (e.g. recovery of all inoculated samples) | 0 | Assessment is complete | Ignore Score Total | Refer to Fit-for-Purpose Result Analysis Tab | |
| | | | | | Total: | 10 |

Example #3: *L. monocytogenes* in Strawberry Ice Cream

Risk Assessment Score:

[Return to risk assessment](#)

Test Method Evaluation Levels



Test method evaluation levels and associated study design schemes determined by risk assessment scoring system.

| Level | Inoculation level | Inoculation level, CFU | Number of test portions | Inoculating Cells | Analysis | When to Use: | Notes |
|----------------------------|-------------------|------------------------|-------------------------|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Full Matrix Validation | High | 20-30 | 5 | Fresh culture or stressed e.g. by heat, drying or freezing | Presumptive results compared to reference method. Equivalent results required as determined by dPOD calculations. | Risk assessment score of 13+ | If no published validation exists, validation must demonstrate the inclusivity and exclusivity of the method. If a narrow published validation includes inclusivity and exclusivity studies, these need not be repeated. "Low " inoculation level should give 25 - 75 % positivity rate. |
| | Low | 0.2-5 | 20 | | | | |
| | None | 0 | 5 | | | | |
| Moderate Matrix Evaluation | High | 20-30 | 2 | Fresh culture or stressed e.g. by heat, drying or freezing | Presumptive results compared to reference method. | Risk assessment score of 6-12 | |
| | Low | 0.2-5 | 10 | | | | |
| | None | 0 | 2 | | | | |
| Minimal Matrix Evaluation | High | 20-30 | 1 - 7 | Fresh culture or stressed e.g. by heat, drying or freezing | 100 % correct response | Risk assessment score of 2-5 | |
| | None | 0 | 0-1 | | | | |

All matrices should be processed at intended-use test portion size and enrichment protocol

“Moderate Matrix Evaluation”

- Recommended for a risk assessment score of **6 to 12**
 - 2 high-level 2-10 CFU/test portion
 - 10 low-level (fractional) 0.2-2 CFU/test portion
 - 2 uninoculated test portions
- Paired results align with cultural confirmation
- No false positive or false negative results



Example #4: *E. coli* O157:H7 in Flour

- Real-Time PCR Method AOAC PTM validated for: Raw beef products, raw milk, spinach and lettuce

RISKS:

➔ Food Category not validated

➔ Matrix associated with O157 outbreaks




VS.



Fresh produce and fruits

Dried cereals, fruits, nuts, seeds and vegetables



Example #4: *E. coli* O157:H7 in Flour

| Risk assessment for suggested evaluation level | | | | | | |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------------------------|--------------------|----------------------------------------------|------------|
| No. | Question | Yes | | No | | Your score |
| | | Score | If Yes, Next Step: | Score | If No, Next Step: | |
| 5A | Does the matrix fit into an AOAC or ISO 16140-2:2016 group (and subcategory - if listed) containing a validated representative example? | 0 | Go to 5B | 10 | Go to 7A | 10 |
| 5B | Is the similar representative example (from 5A) validated at the intended test portion size, or larger? | 0 | Go to 5C | 0 | Go to 5D | |
| 5C | Is the similar representative example (from 5A) validated at the intended enrichment ratio? | 0 | Go to 6A | 0 | Go to 5D | |
| 5D | Does the matrix have a high risk association with the target analyte? | 10 | Go to 6A | 4 | Go to 6A | |
| 6A | Does the new matrix contain inclusions (e.g. ice cream with almonds vs ice cream)? | 0 | Go to 6B | 0 | Go to 7A | |
| 6B | Is the matrix inclusion representative of a matrix already validated by the method? | 0 | Go to 6C | 5 | Go to 7A | |
| 6C | Is the new matrix inclusion enrichment procedure the same as the validated representative example (e.g. do almonds have the same enrichment procedure as ice cream)? | 0 | Go to 7A | 2 | Go to 7A | |
| 7A | Does the matrix or any inclusions present have known ability to inhibit growth of the organism in enrichment or method detection chemistry? | 0 | Go to 7B | 0 | Assessment is complete | 0 |
| 7B | Has a Fit-for-Purpose Test been performed? | 0 | Go to 7C | 5 | Assessment is complete | 5 |
| 7C | Were the results of the Fit-for-Purpose Test acceptable? (e.g. recovery of all inoculated samples) | 0 | Assessment is complete | Ignore Score Total | Refer to Fit-for-Purpose Result Analysis Tab | |
| Total: | | | | | | 15 |

Example #4: *E. coli* O157:H7 in Flour

Risk Assessment Score:

[Return to risk assessment](#)

Test Method Evaluation Levels

Test method evaluation levels and associated study design schemes determined by risk assessment scoring system.

| Level | Inoculation level | Inoculation level, CFU | Number of test portions | Inoculating Cells | Analysis | When to Use: | Notes |
|----------------------------|-------------------|------------------------|-------------------------|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Full Matrix Validation | High | 20-30 | 5 | Fresh culture or stressed e.g. by heat, drying or freezing | Presumptive results compared to reference method. Equivalent results required as determined by dPOD calculations. | Risk assessment score of 13+ | If no published validation exists, validation must demonstrate the inclusivity and exclusivity of the method. If a narrow published validation includes inclusivity and exclusivity studies, these need not be repeated. "Low " inoculation level should give 25 - 75 % positivity rate. |
| | Low | 0.2-5 | 20 | | | | |
| | None | 0 | 5 | | | | |
| Moderate Matrix Evaluation | High | 20-30 | 2 | Fresh culture or stressed e.g. by heat, drying or freezing | Presumptive results compared to reference method. | Risk assessment score of 6-12 | |
| | Low | 0.2-5 | 10 | | | | |
| | None | 0 | 2 | | | | |
| Minimal Matrix Evaluation | High | 20-30 | 1 - 7 | Fresh culture or stressed e.g. by heat, drying or freezing | 100 % correct response | Risk assessment score of 2-5 | |
| | None | 0 | 0-1 | | | | |

All matrices should be processed at intended-use test portion size and enrichment protocol

“Full Matrix Validation”

- Recommended for a risk assessment score of **13+** using the Matrix Evaluation Level Assessment Tool
- **Will be covered in Part 3**
- Define the appropriate method protocol for the new matrix
- Parameters based on **AOAC Appendix J- 4.1.3 Matrix Study**

| Evaluation level | Number of spiked test portions | Inoculation level, CFU/test portion | Inoculating cells | Analysis |
|------------------------|--------------------------------|-------------------------------------|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Full matrix validation | 5 | 2-10 | Fresh culture or heat stressed | Presumptive results compared with confirmation results and reference method to demonstrate no statistical difference between the methods |
| | 20 | 0.2-2 | | |
| | 5 | 0 | | |

Acknowledgements

We would like to acknowledge:

- The International Association For Food Protection Foundation
- Members of Alternative Laboratory Methods PDG
- Authors of the publications:
 - *Patrick M. Bird*
 - *Megan S. Brown*
 - *Sharon L. Brunelle*
 - *W. Evan Chaney*
 - *Joy E. Dell'Aringa*
 - *LeAnn A. Hahn*
 - *Charles Kennett*
 - *Wilfredo Dominguez*
 - *Gabriela Lopez Velasco*
 - *J. David Legan*
 - *Nisha Corrigan*
 - *Ryan D. Maus*
 - *Stephanie Pollard*
 - *Laurie S. Post*
 - *Alexandria VanAusdall*
 - *Christina Barnes*
 - *Kristen A. Hunt*
 - *Sophie Pierre*
 - *Patricia Rule*
 - *Nikki Taylor*
 - *Julie Weller*
 - *Amanda Brookhouser-Sisney*

Questions

Submit questions into the chat

Amanda Brookhouser-Sisney abrookhouser-sisney@midwestlabs.com

Nisha Corrigan ncorrigan@hygiena.com

Jaya Sundaram JSundaram@wtiinc.com

Upcoming Webinars

December 13, 2023, 11:00 AM Building a Culture – The Tools and Tips You Need to Succeed

December 14, 2023, 9:00 AM Impact of Water Use and Reuse in Food Production and Processing on Food Safety at the Consumer Phase: Focus on the Fresh Fruit and Vegetable Products Sector

<https://www.foodprotection.org/events-meetings/webinars/>

Be sure to follow us on social media



InternationalAssociationforFoodProtection



@IAFPFOOD



international-association-for-food-protection



IAFPFood

This webinar is being recorded and will be available for access by **IAFP members** at www.foodprotection.org within one week.

Not a Member? We encourage you to join today.

For more information go to: www.FoodProtection.org/membership/

All **IAFP webinars** are supported by the IAFP Foundation with no charge to participants.

Please consider making a donation to the [IAFP Foundation](#) so we can continue to provide quality information to food safety professionals.